Jove
Visualize
Contact Us

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Cancer discovery·2026
Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026
Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026
Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026
Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Mutation Load Offers Biomarker in SCLC

    Cancer Discovery
    |November 5, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Tumor mutation burden is a promising biomarker for small cell lung cancer. Patients with high tumor mutation burden showed better response to checkpoint inhibitors.

    More Related Videos

    MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
    08:14

    MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

    Published on: October 26, 2017

    16.3K
    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.6K

    Related Experiment Videos

    Last Updated: Feb 19, 2026

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.8K
    MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
    08:14

    MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

    Published on: October 26, 2017

    16.3K
    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.6K

    Area of Science:

    • Oncology
    • Genomics
    • Immunotherapy

    Background:

    • Small cell lung cancer (SCLC) treatment remains challenging.
    • Predictive biomarkers are crucial for optimizing SCLC therapy.
    • Tumor mutation burden (TMB) is an emerging biomarker in cancer.

    Purpose of the Study:

    • To evaluate the predictive value of TMB in SCLC patients treated with checkpoint inhibitors.
    • To explore the association between TMB and response duration to immunotherapy.

    Main Methods:

    • An exploratory analysis was conducted.
    • Data from patients with small cell lung cancer were analyzed.
    • Tumor mutation burden was assessed as a predictive biomarker.

    Main Results:

    • Patients with high tumor mutation burden (TMB) demonstrated a higher likelihood of response to checkpoint inhibitors.
    • Patients with high TMB also experienced longer response durations.
    • A significant correlation between TMB and immunotherapy efficacy was observed.

    Conclusions:

    • TMB is a promising predictive biomarker for SCLC patients.
    • High TMB may predict favorable outcomes with checkpoint inhibitor therapy in SCLC.
    • Further validation studies are warranted to confirm TMB's role in SCLC treatment decisions.